发明名称 |
METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY |
摘要 |
The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections. |
申请公布号 |
WO2014184741(A1) |
申请公布日期 |
2014.11.20 |
申请号 |
WO2014IB61409 |
申请日期 |
2014.05.13 |
申请人 |
CELLECTIS |
发明人 |
GALETTO, ROMAN;GOUBLE, AGNES;GROSSE, STEPHANIE;MANNIOUI, CECILE;POIROT, LAURENT;SCHARENBERG, ANDREW;SMITH, JULIANNE |
分类号 |
C12N5/0783;C07K14/735;C07K16/28 |
主分类号 |
C12N5/0783 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|